8
Participants
Start Date
March 5, 2015
Primary Completion Date
July 9, 2019
Study Completion Date
July 9, 2019
Lenalidomide
2.5 mg by mouth daily on Day -2 to Day +14.
Rituximab
375 mg/m2 by vein on Day -5 for participants with B-cell cancer.
Fludarabine
"Lymphodepleting Chemotherapy Option #1: Fludarabine 25 mg/m2 by vein on Days -5 to -3.~Lymphodepleting Chemotherapy Option #2: Fludarabine 25 mg/m2 by vein over 1 hour on Day -6 to -2.~Lymphodepleting Chemotherapy Option #3: Fludarabine 30 mg/m2 by vein over 1 hour on Days -6 to -2"
Cyclophosphamide
"Lymphodepleting Chemotherapy Option #1: Cyclophosphamide 200 mg/m2 by vein on Days -5 to -3.~Lymphodepleting Chemotherapy Option #2: Cyclophosphamide 60 mg/kg by vein over 3 hours on Days -5 and -4."
NK Cells
"Participant assigned to a dose level of NK cells based on when joined study. Starting dose level of NK cells 1 x 10\^7 NK cells/kg given by vein on Day 0.~NK Cell Infusion Expansion Phase: Maximum tolerated dose of NK cells from Induction Phase."
Cytarabine
Cytarabine 2 mg/m2 by vein on Days -6 to -2.
University of Texas MD Anderson Cancer Center, Houston
Collaborators (1)
The Leukemia and Lymphoma Society
OTHER
Celgene Corporation
INDUSTRY
M.D. Anderson Cancer Center
OTHER